<DOC>
	<DOCNO>NCT02340130</DOCNO>
	<brief_summary>This open-label , non-controlled , non-randomised , prospective safety study patient rhinitis allergic rhinoconjunctivitis , control asthma , clinically relevant sensitisation dust mite Pyroglyphidae Glycyphagidae family .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Depigmented Modified Allergen Extract Two Mites Subjects With Allergic Rhinitis Rhinoconjunctivitis , With Controlled Allergic Asthma</brief_title>
	<detailed_description>The objective evaluate safety tolerability administration two allergen extract dust mite mixture 200 DPP/ml ( DP/MG/14-1 Dermatophagoides pteronyssinus / Blomia tropicalis DP/MG/14-2 Dermatophagoides pteronyssinus / Lepidoglyphus destructor ) use rush build-up phase patient allergic rhinitis rhinoconjunctivitis , control asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>1 . Subject provide appropriately sign date write informed consent . 2 . Men woman age 18 year 70 year age Visit 1 . 3 . Has FEV1 value 80 % predict normal value Visit 1 . 4 . Individuals suffer perennial allergic rhinitis rhinoconjunctivitis moderatesevere least preceding year , control asthma , cause double sensitization Dermatophagoides pteronyssinus ( DPT ) Lepidoglyphus destructor Dermatophagoides pteronyssinus Blomia tropicalis . 5 . Patients sensitize coallergens tree pollen , grass weed , fungi animal epithelials participate study symptomatic . 6 . If female nonchildbearing potential , subject must postmenopausal least 1 year surgically sterile . 7 . If female childbearing potential , subject must nonlactating nonpregnant must correctly use effective method contraception study . 1 . Any contraindication treatment allergen specific immunotherapy . 2 . Subjects previous history anaphylaxis . 3 . Patients hospital admission due asthma exacerbation within 1 year prior V1 . 4 . Has uncontrolled asthma , accord Global Initiative Asthma Guidelines ( GINA 2010 ) . 5 . Acute chronic infectious conjunctivitis . 6 . Has acute chronic inflammatory infectious airway disease . 7 . Has chronic structural disease affect organ ( e.g . eye , nose , lung ) . 8 . History presence confirm potential disease immune system include autoimmune disease immune deficiency actual clinical relevance . 9 . Has disease prohibits use adrenaline ( e.g. , hyperthyroidism ) . 10 . Has severe uncontrolled disease could increase risk subject participate study , include limited , follow : cardiovascular insufficiency , severe unstable lung disease , endocrine disease , clinically significant renal hepatic disease haematological disord</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>